Skip to main content

Four JAK Inhibitors Have Comparable Efficacy, Safety for RA

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 1, 2023.

By Elana Gotkine HealthDay Reporter

FRIDAY, Dec. 1, 2023 -- For patients with rheumatoid arthritis, the efficacy and safety of four Janus kinase (JAK) inhibitors is comparable, according to a study published online Nov. 1 in Rheumatology.

Shinya Hayashi, M.D., from the Kobe University Graduate School of Medicine in Japan, and colleagues conducted a multicenter, retrospective study comparing the efficacy and safety of tofacitinib (TOFA), baricitinib (BARI), peficitinib, and upadacitinib in 622 patients in real-world clinical settings. In the four treatment groups, patient backgrounds were matched using propensity score-based inverse probability of treatment weighting.

The researchers found that among the four JAK inhibitor groups, the retention and discontinuation rates until six months after drug initiation did not differ significantly. Furthermore, no differences were seen in mean Clinical Disease Activity Index (CDAI) value, CDAI remission rate, or CDAI-low disease activity (LDA) rate at six months after drug initiation. Predictive factors for resistance to CDAI-LDA achievement for JAK inhibitor treatment included baseline CDAI (odds ratios, 1.09 for tofacitinib and 1.07 for baricitinib), baseline C-reactive protein (CRP; odds ratio, 1.32 for tofacitinib), baseline glucocorticoid dose (odds ratio, 1.18 for baricitinib), and number of previous biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs; odds ratio, 1.36 for baricitinib).

"Baseline CRP titer and CDAI were identified as predictive factors for resistance to LDA achievement with TOFA," the authors write. "Baseline glucocorticoid dose, baseline CDAI, and number of previous b/tsDMARDs were identified as the predictive factors with BARI."

Several authors disclosed ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

Rheumatology Workforce Increased 20 Percent From 2009 to 2019

THURSDAY, March 14, 2024 -- The overall number of clinically active rheumatology providers grew more than 20 percent during the last decade, according to a study published online...

Risk for Autoimmune Inflammatory Rheumatic Disease Increased After SARS-CoV-2

TUESDAY, March 5, 2024 -- Patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have an increased risk for incident autoimmune inflammatory...

Sinusitis Linked to Increased Risk for Subsequent Rheumatic Disease

WEDNESDAY, Feb. 28, 2024 -- A history of sinusitis is associated with an increased incidence of rheumatic disease, according to a study published online Feb. 27 in RMD...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.